Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
Clicks: 207
ID: 6484
2010
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
75.3
/100
207 views
165 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection Lisa M Chirch, Roy T SteigbigelDivision of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USAAbstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.Keywords: raltegravir, integrase, human immunodeficiency virus, drug resistance| Reference Key |
lisa2010raltegravirinfection
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Lisa M Chirch;Roy T Steigbigel and |
| Journal | Infection and drug resistance |
| Year | 2010 |
| DOI | 10.2147/IDR.S9689 |
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.